RenovoRx, Inc.

NASDAQ:RNXT

Biotechnology

Healthcare
$1.12 -0.86%

-$0.01 today

Market cap
$54.04M
Beta
0.99
P/E (TTM)
-3.4
EPS (TTM)
-$0.32
52W Low $0.70High $1.45

Volume 0.84M

Average 0.29M

RNXT Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

RenovoRx, Inc.NASDAQ: RNXT

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $1.23M fell 25.2% year over year, behind the -8.9% change in trailing-twelve-month research & development. Sequentially, it fell 18.2% from the prior quarter. Over 3 fiscal years it compounded at +13.4% a year.

Context

  • Research & development amounted to 558.2% of revenue in FY2025, down 13453.4 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -25.2% toward the trailing-twelve-month pace of -8.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.23M-18.2% QoQ
Last fiscal yearDec 2025
$6.27M+4.0% YoY
LTMMar 2026
$5.84M-8.9% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-25.2%——
1 year+4.0%——
3-year CAGR+13.4%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
6.27M USD
Year-over-year change
+4.0%
4-year CAGR
+19.8%

Research & Development vs competitors

How RNXT compares with its peers on the latest reported figures

  • RNXT's LTM Mar 2026 research & development of $5.84M is the lowest of the 6 companies compared; the peer median is $15.03M.
  • Its year-over-year change of -8.9% is the 4th highest of 6, against a peer median of -1.8%.
  • Research & development amounts to 392.2% of revenue for RNXT, versus a peer median of 56.6%.
RNXT Competitors Peer median
Research & Development for RNXT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ANVSAnnovis Bio, Inc.LTM Mar 2026$16.74B +90463.6%+15.1%—
PYPDPolyPid Ltd.LTM Mar 2026$23.45M -1.8%-5.3%—
CELUCelularity Inc.LTM Dec 2025$15.03M -13.6%-42.3%56.6%
MAIAMAIA Biotechnology, Inc.LTM Mar 2026$14.87M +36.6%+1076.5%—
LTRNLantern Pharma Inc.LTM Mar 2026$9.98M -34.1%+10.2%—
RNXTRenovoRx, Inc.LTM Mar 2026$5.84M -8.9%+13.4%392.2%
Peer median (excluding RNXT) $15.03M-1.8%+10.2%56.6%

Competitors are the stored peer set for RNXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00043K1.12M
Cost of Revenue0000327K
Gross Profit00043K796K
Gross Margin———100.0%70.9%
Research & Development3.04M4.3M5.67M6.03M6.27M
Selling, General & Admin2.63M5.65M5.73M4.99M7.04M
Operating Expenses5.67M9.95M11.4M11.01M13.31M
Depreciation & Amortization9K6K6K02K
EBITDA(5.48M)(9.83M)(10.12M)(8.81M)(11.17M)
EBITDA Margin———-20497.7%-994.3%
Operating Income(5.67M)(9.95M)(11.4M)(10.97M)(12.51M)
Operating Margin———-25511.6%-1114.0%
Interest Income70K57K0384K427K
Interest Expense904K57K108K00
Other Income / Expenses(653K)61K1.16M2.16M1.34M
Income Before Tax(6.32M)(9.89M)(10.23M)(8.81M)(11.17M)
Pre-Tax Margin———-20497.7%-994.5%
Income Tax Expense00000
Net Income(6.32M)(9.89M)(10.23M)(8.81M)(11.17M)
Net Margin———-20497.7%-994.5%
EPS (Basic)(0.40)(0.54)(0.50)(0.37)(0.32)
EPS (Diluted)(0.40)(0.54)(0.50)(0.37)(0.32)
Weighted Avg Shares17.87M18.1M20.58M23.61M35.33M
Weighted Avg Shares (Diluted)17.87M18.1M20.58M23.61M35.33M

RenovoRx, Inc.

NASDAQ:RNXT

Intrinsic Alpha fair value

Locked

Current Price

$1.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.